Home › Medulloblastoma
Pag-aaral pangklinika para sa Medulloblastoma na nagre-recruit sa U.S.
23 pag-aaral para sa Medulloblastoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Washington, DC8 pag-aaral
- St. Louis, MO6 pag-aaral
- Durham, NC4 pag-aaral
- Seattle, WA4 pag-aaral
- Orlando, FL4 pag-aaral
- Tampa, FL4 pag-aaral
- New York City, NY4 pag-aaral
- Philadelphia, PA4 pag-aaral
- Miami, FL4 pag-aaral
- Houston, TX4 pag-aaral
- Boston, MA3 pag-aaral
- Ann Arbor, MI3 pag-aaral
- Chicago, IL3 pag-aaral
- Minneapolis, MN3 pag-aaral
- Columbus, OH3 pag-aaral
- Hartford, CT3 pag-aaral
- San Francisco, CA3 pag-aaral
- Cincinnati, OH3 pag-aaral
- St. Petersburg, FL3 pag-aaral
- Austin, TX3 pag-aaral
- Charlotte, NC3 pag-aaral
- Dallas, TX3 pag-aaral
- Little Rock, AR3 pag-aaral
- San Diego, CA3 pag-aaral
- Mountain View, CA3 pag-aaral
- Memphis, TN3 pag-aaral
Ayos sa estado
- Alabama3 pag-aaral
- Arkansas3 pag-aaral
- California6 pag-aaral
- Connecticut3 pag-aaral
- District of Columbia7 pag-aaral
- Florida6 pag-aaral
- Georgia3 pag-aaral
- Illinois3 pag-aaral
- Kentucky3 pag-aaral
- Maryland3 pag-aaral
- Massachusetts3 pag-aaral
- Michigan4 pag-aaral
- Minnesota3 pag-aaral
- Missouri6 pag-aaral
- New Jersey3 pag-aaral
- New York5 pag-aaral
- North Carolina4 pag-aaral
- Ohio3 pag-aaral
- Pennsylvania5 pag-aaral
- Tennessee5 pag-aaral
- Texas8 pag-aaral
- Washington4 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT06161519Digoxin Medulloblastoma Study
Nagre-recruitPhase 2
12 Months – 30 Years · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06701812Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
Nagre-recruitPhase 1
Edad 4 hanggang 30 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT06514898Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Nagre-recruitPhase 1
Edad 3 hanggang 25 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT0510629668-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Nagre-recruitPhase 4
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT04081701Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT06193759Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Nagre-recruitPhase 2
Hanggang edad 19 · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT01356290GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Okt 9, 2026 · NCT07087002A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
Nagre-recruitPhase 1
Edad 3 hanggang 22 · Lahat ng kasarian · Na-update Okt 8, 2026 · NCT07698899Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
Nagre-recruitPhase 1/2
Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07346157Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback
Nagre-recruit
Edad 10 hanggang 25 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07830134Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Nagre-recruitPhase 2
59 Months · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05535166HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Nagre-recruitPhase 1
36 Months – 22 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
Nagre-recruitPhase 1
Edad 2 hanggang 21 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07390539Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Nagre-recruitObservasyonal na pag-aaral
Edad 3 hanggang 50 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07242963A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Nagre-recruitPhase 3
Edad 4 hanggang 21 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05382338PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nagre-recruitPhase 2
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05096481DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Nagre-recruitPhase 2
Hanggang edad 21 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT04696029Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Nagre-recruit
12 Months – 39 Years · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05057702Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Nagre-recruitPhase 1
Edad 2 hanggang 25 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06624371Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nagre-recruitPhase 1/2
Edad 4 hanggang 39 · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT05278208CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT07085325Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Nagre-recruitPhase 1
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT04185038Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.